In addition, gains in cyclin-dependent kinase 2 (CDK2) and erb-b2 receptor tyrosine kinase 3 (ERBB3) were found only in recurrent lesions (37.5% and 37.5%, respectively) but not in the corresponding primary tumor controls [42]. Here, CDK2 is linked to neoplasm.